Clinical trials: SARS-COV 2
SARS-CoV 2, COVID-19
Favipiravir vs Hydroxychloroquine vs Control in COVID -19
Hydroxychloroquine is widely used to treat autoimmune diseases. Clinical investigation has found that a high concentration of cytokines were detected in the plasma of critically ill patients infected with SARS-CoV-2, therefore…
- Trial name
- NCT04387760
- Testing
- Hydroxychloroquine, Favipiravir, Routine care for COVID-19 patients
- Where
- Bahrain
- Volunteers
- 150 people
- Sponsor
- Royal College of Surgeons in Ireland - Medical University of Bahrain
SARS-CoV 2, COVID19
Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome
The administration of Calcifediol in patients with COVID-19, will reduce the development of SARS and the worsening of the various phases of the syndrome.
- Conditions
- SARS-CoV 2, COVID19, SARS (Severe Acute Respiratory Syndrome), Cytokine Release Syndrome
- Trial name
- COVIDIOL (NCT04366908)
- Testing
- BAT + Calcifediol, BAT
- Where
- Spain
- Volunteers
- 517 people
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba
Healthy Participants
Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants
This is a Phase 1, open label, single dose, randomized, 2-treatment, 2-sequence, 2-period crossover study to evaluate the effect of high-fat meal on the relative bioavailability of PF-07321332 boosted with ritonavir following…
- Trial name
- NCT05129475
- Testing
- PF-07321332/ritonavir, Ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Viral Infections, Influenza
Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections
The goal of this clinical trial is to evaluate the effects of myxovirus resistance protein A (MxA)-guided antiviral treatment on treatment duration and adverse outcomes in adults hospitalized with influenza or COVID-19, compared…
- Conditions
- Respiratory Viral Infections, Influenza, SARS CoV 2 Infection
- Trial name
- NCT07892872
- Testing
- Baseline MxA testing, Serial MxA testing, MxA result feedback and antiviral treatment recommendations
- Where
- China
- Volunteers
- 618 people
- Sponsor
- Capital Medical University
COVID-19, SARS-CoV 2
EXercise TRAining and Sedentary Lifestyle on Clinical Outcomes in Patients With COVID-19
The present study aims to assess the impact of exercise training, physical activity, and sedentary lifestyle on clinical outcomes in surviving patients infected with the severe acute respiratory syndrome coronavirus 2…
- Conditions
- COVID-19, SARS-CoV 2, Corona Virus Infection, Sedentary Behavior
- Trial name
- WHO (NCT04396353)
- Testing
- Electronic questionnaire
- Where
- Brazil
- Volunteers
- 1,574 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
Corticosteroids, Covid19
Short Term Corticosteroids in SARS-CoV2 Patients
The investigators reviewed the charts of SARS-CoV-2 patients with pneumonia and moderate to severely elevated CRP and worsening hypoxemia who were treated with early, short-term dexamethasone.
- Conditions
- Corticosteroids, Covid19, SARS-CoV 2, Steroids
- Trial name
- NCT04445506
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- The Miriam Hospital
SARS CoV 2 Infection
Inhibition of Bradykinin in COVID-19 Infection With Icatibant
There is excess accumulation of bradykinin during symptomatic SARS CoV-2 lung infection. Bradykinin causes oedema in the lung, with reduced oxygen. It also causes vasodilation, hypotension and cytokine release.
- Trial name
- ICASARS (NCT05407597)
- Testing
- Icatibant, 0.9% Sodium Chloride Injection
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Belfast Health and Social Care Trust
COVID-19, Vaccine-Preventable Diseases
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
The purpose of this research study is to find out how well two different 2023-2024 updated COVID-19 vaccines protect people from COVID-19 (the disease caused by the SARS-CoV-2 virus), and to determine if getting a 2023-2024…
- Conditions
- COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection
- Trial name
- BEEHIVE (NCT06065176)
- Testing
- Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
- Where
- United States
- Volunteers
- 1,188 people, healthy volunteers welcome
- Sponsor
- Sarang K. Yoon, DO, MOH
Coronavirus Infection, SARS-CoV 2
Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19
This is a phase I/IIa trial to evaluate the safety, tolerability and immunological profile of INO-4800 administered by intradermal (ID) injection followed by electroporation (EP) using the CELLECTRA® 2000 device in healthy adults…
- Trial name
- NCT04447781
- Testing
- INO-4800, CELLECTRA® 2000, Saline-sodium citrate (SSC) buffer
- Where
- 2 sites in South Korea
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- International Vaccine Institute
COVID-19, SARS CoV 2 Infection
NIH RECOVER Tissue Pathology: Understanding the Long-Term Impact of COVID-19
The Post-Acute Sequelae of SARS-CoV-2 (PASC) Autopsy Study is a cross-sectional study designed to define and characterize the epidemiology, natural history, clinical spectrum, and underlying mechanisms of post-acute effects of…
- Trial name
- NCT05292274
- Where
- United States
- Volunteers
- 304 people
- Sponsor
- NYU Langone Health
Anosmia, SARS CoV 2 Infection
Anosmia and Covid-19
Our study aims to determine the prevalence of anosmia in patients SARS-Cov-2/Covid-19 infection (both by symptom reporting and smell testing), the efficacy of early olfactory training for the treatment of anosmia caused by…
- Trial name
- COVANOS (NCT05246059)
- Testing
- Olfactory Training
- Where
- 4 sites in United Kingdom
- Volunteers
- 63 people
- Sponsor
- University College, London
Covid-19, SARS-CoV 2
Baricitinib Compared to Standard Therapy in Patients With COVID-19
There is urgent need of an effective therapy for Covid-19. To date, the best treatment of SARS-CoV-2 infection is unknown. Baricitinib has been identified as potential treatment for 2019-nCoV acute respiratory disease, because of…
- Conditions
- Covid-19, SARS-CoV 2, SARS Pneumonia
- Trial name
- BARICIVID-19 (NCT04393051)
- Testing
- Baricitinib Oral Tablet
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Covid19
COVID-19 Personal Protective Equipment for Vaccinated Health Workers and Convalescents
The aim of the trial is to assess the safety of using simplified personal protective equipment (PPE) for vaccinated or COVID-19 convalescent healthcare workers working in COVID-19 ICU or COVID-19 wards.
- Trial name
- NCT06158724
- Testing
- Personal Protective Equipment
- Where
- Slovenia
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Medical Centre Ljubljana
COVID, SARS-CoV 2
COVID-19: Herd Immunity Study in the Czech Republic
The aim of the SARS-CoV-2-CZ-Preval study is to quantify the prevalence of individuals with a history of SARS-CoV-2 coronavirus infection in the Czech population, except for those diagnosed with COVID-19 by methods based on…
- Trial name
- SARSCoV2CZPrev (NCT04401085)
- Testing
- SARS-CoV-2 diagnostic rapid test, Quantitative analysis of SARS-CoV-2 antibodies
- Where
- Czechia
- Volunteers
- 27,000 people, healthy volunteers welcome
- Sponsor
- Institute of Health Information and Statistics of the Czech Republic
Covid19, SARS-CoV Infection
Infection Control for Severe Acute Respiratory Syndrome Coronavirus 2
The investigators aim to develop expert consensus statements on infection control management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in intensive care units (ICU).
- Conditions
- Covid19, SARS-CoV Infection, SARS Pneumonia, Coronavirus Infection
- Trial name
- IC-COVID-19 (NCT04665960)
- Where
- United Arab Emirates
- Volunteers
- 35 people
- Sponsor
- NMC Specialty Hospital
SARS-CoV 2
Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection
Phase I / II multicentre, randomized and controlled clinical trial to evaluate the efficacy of treatment with hyperimmune plasma obtained from convalescent antibodies of COVID-19 infection.
- Trial name
- NCT04366245
- Testing
- Hyperimmune plasma, Standard of care for SARS-CoV-2 infection
- Where
- 14 sites in Spain
- Volunteers
- 72 people
- Sponsor
- Andalusian Network for Design and Translation of Advanced Therapies
SARS-CoV 2, Immunization; Infection
Study to Determine the Immunization Status Among Nephrological Health Care Personnel Against SARS-CoV-2 in a Single Center Over the Course of 12 Months During the Worldwide COVID-19 Pandemic.
Infections with Corona-Viruses have shown to be a menace for patients with comorbidities such as hypertension, diabetes, cardiovascular disease or immunosuppression.
- Trial name
- CONEC (NCT04347694)
- Where
- Austria
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Influenza A Infection, Influenza B Virus Infection
Age Related Differences in Respiratory Immune Responses in Influenza Virus Infection
The goal of this observational study is to understand immune responses to viral airway infection in adults, including the elderly.
- Conditions
- Influenza A Infection, Influenza B Virus Infection, SARS CoV 2 Infection, RSV Infection
- Trial name
- NPA-DC (NCT06401720)
- Where
- 5 sites in Sweden
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
COVID-19, Neuro-Degenerative Disease
Randomised Clinical Trial to Evaluate the Efficacy of an Online Cognitive Rehabilitation Programme (COPERIA-COG) for Patients With Persistent COVID-19
The pandemic caused by SARS-CoV-2 infection has led to the emergence of diffuse and heterogeneous persistent symptoms in addition to the well-known acute symptoms, which have come to be referred to as persistent COVID.
- Conditions
- COVID-19, Neuro-Degenerative Disease, Psychological, SARS CoV 2 Infection
- Trial name
- COPERIA-COG (NCT05629897)
- Testing
- Sessions of cognitive stimulation
- Where
- 2 sites in Spain
- Volunteers
- 88 people
- Sponsor
- Fundacin Biomedica Galicia Sur
Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis
Medicine-induced Cardiac Hemodialysis on COVID-19
The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system.
- Conditions
- Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis, Vaccines, Myocarditis Allergic
- Trial name
- NCT05711810
- Testing
- Nifedipine 30 MG, Kangzhu BPCB0A-3A, Low Mobility
- Where
- China
- Volunteers
- 1 people
- Sponsor
- Yang I. Pachankis